Compare Keysight Technologies Inc (KEYS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Twist Bioscience Corp — how do they compare? Keysight Technologies Inc trades at $382.61 (market cap $63.79B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Keysight Technologies Inc is far larger — about 6.3× Twist Bioscience Corp's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and Twist Bioscience Corp for 27 Days on average.
| KEYS | TWST | |
|---|---|---|
Market Cap | $63.79B | $10.08B |
Volume | 1,435,384 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $387.90 | $205.00 |
52-Week Low | $159.49 | $25.45 |
Typical Hold Time | 56 Days | 27 Days |
Enterprise Value | $63.93B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $374.66, down 1.79% on the day, with strong technical momentum indicated by bullish moving averages and a consensus price target of $416.63 representing 11.2% upside. The company demonstrates robust fundamentals with Q2 2026 EPS of $3.07 beating expectations by 24%, supported by 56% order growth driven by AI infrastructure demand and 6G development opportunities. Revenue recovery to $5.38B in 2025 and net income margin expansion to 19.14% reflect improving operational efficiency.
KEYS presents compelling growth prospects from AI and 6G tailwinds, though elevated valuation multiples (P/E 50.7) and supply chain constraints pose near-term risks. Wall Street maintains strong bullish sentiment with 81% buy ratings, while technical indicators suggest the stock is testing key resistance at $375 with support at $370. The combination of accelerating earnings, strategic positioning in high-growth markets, and institutional confidence supports a positive medium-term outlook despite valuation concerns.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
